Report
Kelsey Tsai
EUR 147.86 For Business Accounts Only

Relaunching Coverage of Parexel With a $62 Fair Value Estimate; Shares Fairly Valued

We are relaunching coverage of Parexel, a global contract research organization that primarily caters to pharma and biotech companies. We are maintaining our $62 per share fair value estimate and narrow moat rating. Parexel also has exposure to the regulatory consulting and informatics markets, but only the company’s late-stage contract research organization, which accounts for the majority of sales, exhibits competitive advantages over smaller peers, in our view. We are updating the moat trend ...
Underlying
PAREXEL International Corporation

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Kelsey Tsai

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch